Confronting the “silent killer”: Advances in HCV testing and treatment
            Siemens Healthcare Global Website


Confronting the “silent killer”: Advances in HCV testing
and treatment

Please select an option below:

> Please click here to register or login



Dr. John Ward, MD
Director, Division of Viral Hepatitis
Atlanta, GA, USA

HCV infection is a significant contributor to chronic liver disease (CLD) worldwide. In the US, HCV is the leading cause of liver transplants. To address this growing threat, the CDC has recently issued a significant change to HCV screening guidelines to better identify undiagnosed cases that can lead to advanced disease and missed opportunities for treatment.

This program has been designated for 1.0 PACE continuing education credit.*

At the end of the presentation, attendees will be able to:

  • Describe HCV natural history and epidemiology.
  • Describe the key laboratory assays involved in an HCV diagnosis.
  • Understand the value in the “birth cohort” screening recommendation.
  • Discuss new treatment modalities that are expected to dramatically improve treatment efficacy.

Siemens continues to provide educational opportunities on key topics important to laboratory science and clinical implementation. We invite you to participate in other Siemens webinars and to check back often. As your trusted partner, Siemens is committed to helping you stay on the forefront of laboratory medicine.

*There is a charge of $10.00 plus local tax for each half or full hour of CE credit. Purchase of CE credit is optional. Non-accredited customer participation in Siemens educational offerings and programs remains complimentary.

> Home
> Test Your System
> Help


           Siemens Healthcare Diagnostics Inc. 2007-2009  |  Corporate Information  |  Privacy Statement  |  Terms of Use